Home Hematology and Oncology Prevalence of Antiphospholipid Syndrome Up for Roma SLE

Prevalence of Antiphospholipid Syndrome Up for Roma SLE

Roma systemic lupus erythematosus patients also have significantly higher prevalence of abortions

WEDNESDAY, June 14, 2017 (HealthDay News) — The prevalence and risk of antiphospholipid syndrome (APS) is higher for Roma versus Caucasian systemic lupus erythematosus (SLE) patients, according to a study published online June 7 in the International Journal of Rheumatic Diseases.

Victoria Manzano-Gamero, from the Complejo Hospitalario Universitario de Granada in Spain, and colleagues conducted a cross-sectional study including data from 52 Roma and 98 Caucasian SLE patients consecutively attending six hospitals in Spain. The authors compared socio-demographic characteristics, prevalence of APS, and clinical and analytical features of SLE and ALS between ethnic group.

The researchers found that the risk (odds ratio, 2.56; 95 percent confidence interval, 1.02 to 6.39) and prevalence of APS (28.8 versus 13.3 percent; P = 0.027) were increased in Roma SLE patients. They also had a higher prevalence of abortions (23.5 versus 10.2 percent; P = 0.049). A non-significantly higher prevalence of fetal deaths (14.3 versus 5.1 percent; P = 0.106) and thrombotic events (21.1 versus 12.2 percent; P = 0.160) was seen for Roma SLE patients. Roma patients had significantly higher prevalence of arthritis (75.0 versus 57.1 percent; P = 0.034), while the prevalence of serositis, discoid lesions, oral ulcers, and livedo reticularis were non-significantly higher (P = 0.104, 0.191, 0.218, and 0.374, respectively).

“Prevalence and risk of APS were significantly higher in Roma SLE patients,” the authors write. “Furthermore, Roma patients had a significantly higher prevalence of abortions and a non-significant higher prevalence of fetal deaths and thrombotic events.”

Copyright © 2017 HealthDay. All rights reserved.